ADARx Pharmaceuticals Stock
HealthTechLooking to sell ADARx Pharmaceuticals stock or options?
ADARx Pharmaceuticals is a clinical-stage biotechnology company focused on transforming scientific discoveries into life-saving treatments. The company utilizes a proprietary ribonucleic acid (RNA) targeting platform that includes oligonucleotides for inhibition, degradation, and editing, along with innovative oligonucleotide delivery technologies. ADARx Pharmaceuticals is developing an expanding pipeline of RNA-targeting therapeutics aimed at treating a variety of diseases, such as genetic, cardiometabolic, complement-mediated, and central nervous system disorders. This approach enables patients to swiftly treat previously incurable diseases caused by genetic mutations.
Cormorant Asset Management, Marshall Wace, BlackRock, Venrock, Bain Capital Life Sciences, T. Rowe Price Group, Ascenta Capital, Vivo Capital, Commodore Capital, TCG Crossover Management, HBM Partners, The Invus Group, OrbiMed, SR One Capital Management, Redmile Group, HBM Healthcare Investments, Lilly Asia Ventures, Sirona Capital.